Crown Laboratories Acquires Revance Therapeutics, Expanding Aesthetic Portfolio
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
The nearly 2,500-patient study found no benefit from drain use, including among patients considered at higher risk for complications.